Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): Relation to species differences in hepatotoxicity

Drug Metabolism and Disposition

Volumn 33, Issue 2, 2005, Pages 271-281

  Kenny, Jane R ^a,c   Maggs, James L ^a   Tettey, Justice N A ^a,d   Harrell, Andrew W ^b   Parker, Steven G ^b   Clarke, Stephen E ^b   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [6 [[(2,6 DICHLOROPHENYL)THIO]METHYL] 3 (2 PHENYLETHOXY) 2 PYRIDINYL] 2 PROPENOIC ACID; 3 [6 [[(2,6 DICHLOROPHENYL)THIO]METHYL] 3 (2 PHENYLETHOXY) 2 PYRIDINYL] 2 PROPENOIC ACID ACYL GLUCURONIDE; 3 [6 [[(2,6 DICHLOROPHENYL)THIO]METHYL] 3 (2 PHENYLETHOXY) 2 PYRIDINYL] 2 PROPENOIC ACID SULFOXIDE; 3 [6 [[(2,6 DICHLOROPHENYL)THIO]METHYL] 3 (2 PHENYLETHOXY) 2 PYRIDINYL] 2 PROPENOIC ACID SULFOXIDE ACYL GLUCURONIDE; ANTIINFLAMMATORY AGENT; DRUG METABOLITE; GLUCURONIDE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SB 209247; SB 215244; SULFOXIDE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; BILIARY EXCRETION; CATALYSIS; CELL DAMAGE; CHEMICAL REACTION KINETICS; CONCENTRATION RESPONSE; DOG; DRUG CONJUGATION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME RELEASE; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; LIVER SLICE; LIVER TOXICITY; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; SPECIES DIFFERENCE; SULFOXIDATION;

ACRYLATES; ADULT; ANIMALS; DOGS; GLUCURONIDES; HUMANS; LEUKOTRIENE B4; LIVER; MALE; PROTEIN BINDING; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 13444267274     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001677     Document Type: Article

References (40)

1. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem-Biol Interact 145:117-137.
2. Bergmeyer HU and Bernt E (1974) Lactate dehydrogenase. UV-assay with pyruvate and NADPH, in Methods of Enzymatic Analysis (Bergmeyer HU ed) pp 574-579, Verlag Chemie Int., Deerfield Beach, FL.
3. 4 receptor antagonist. J Pharmacol Exp Ther 297:458-466.
4. Boelsterli UA (2002) Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab 3:439-450.
5. Boelsterli UA (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307-322.
6. Bort R, Ponsoda X, Jover R, Gómez-Lechón MJ, and Castell JV (1999) Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 288:65-72.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Brooks CDW and Summers JB (1996) Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 39:2629-2654.
9. Chambers RJ, Marfat A, Antognoli GW, Cheng JB, Damon DB, Kuperman AV, Liston TC, Mebus C, Pillar JS, Shirley JT, and Watson JW (1999) Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LTI receptor antagonists devoid of liver toxicity. Bioorg Med Chem Lett 9:2773-2778.
10. Copple BL, Ganey PE, and Roth RA (2003) Liver inflammation during monocrotaline hepatotoxicity. Toxicology 190:155-169.
11. 1H NMR spectroscopic studies of the reactive α-1-O-acyl isomer formed during acyl migration of S-naproxen β-1-O-acyl glucuronide. Chem Res Toxicol 14:1363-1370.
12. Crooks SW and Stockley RA (1998) Leukotriene B4. Int J Biochem Cell Biol 30:173-178.
13. Dahms M, Lotz R, Lang W, Renner U, Bayer E, and Spahn-Langguth H (1997) Elucidation of phase I and phase II metabolic pathways of rhein: species differences and their potential relevance. Drug Metab Dispos 25:442-452.
14. Daines RA, Chambers PA, Foley JJ, Griswold DE, Kingsbury WD, Martin LD, Schmidt DB, Sham KK, and Sarau HM (1996) (E)-3-[6-[[(2,6-Dichlorophenyl)-thio] methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity. J Med Chem 39:3837-3841.
15. Davis HM, Carpenter DC, Stahl JM, Zhang W, Hynicka WP, and Griswold DE (2000) Human granulocyte CD11b expression as a pharmacodynamic biomarker of inflammation. J Immunol Methods 240:125-132.
16. Essani NA, Bajt ML, Farhood A, Vonderfecht SL, and Jaeschke H (1997) Transcriptional activation of vascular cell adhesion molecule-1 gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Immunol 158:5941-5948.
17. Fretland DJ, Anglin CP, Widomski D, Baron DA, Maziasz T, and Smith PF (1995) Pharmacological activity of the second generation leukotriene B4 receptor antagonist, SC-53228: effects on acute colonic inflammation and hepatic function in rodents. Inflammation 19:503-515.
18. Gill HJ, Tingle MD, and Park BK (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40:531-538.
19. Griffin MR and Scheiman JM (2001) Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. Am J Med 110:33S-37S.
20. Howell SR, Shirley MA, Grese TA, Neel DA, Wells KE, and Ulm EH (2001) Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites and in vitro activity at retinoid receptors. Drug Metab Dispos 29:990-998.
21. James LP, Mayeux PR, and Hinson JA (2003) Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31:1499-1506.
22. Kenny JR, Maggs JL, Meng X, Sinnott D, Clarke SE, Park BK, and Stachulski AV (2004) Syntheses and characterisation of the acyl glucuronide and hydroxy metabolites of diclofenac. J Med Chem 47:2816-2825.
23. King AR and Dickinson RG (1991) Studies on the reactivity of acyl glucuronides: I. Phenolic glucuronidation of isomers of diflunisal acyl glucuronide in the rat. Biochem Pharmacol 42:2289-2299.
24. Kretz-Rommel A and Boelsterli UA (1993) Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 120:155-161.
25. Krumdieck CL, dos Santos JE, and Ho KJ (1980) A new instrument for the rapid preparation of tissue slices. Anal Biochem 104:118-123.
26. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265-275.
27. Maggs JL, Bishop LPD, Edwards G, O'Neill PM, Ward SA, Winstanley PA, and Park BK (2000) Biliary metabolites of β-artemether in rats: biotransformations of an antimalarial endoperoxide. Drug Metab Dispos 28:209-217.
28. Merlani G, Fox M, Oehen H-P, Cathomas G, Renner EL, Fattinger K, Schneemann M, and Kullak-Ublick GA (2001) Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 57:321-326.
29. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA (2002) Glucuronidation of statins in animals: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512.
30. Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, and Davern TJ (2000) Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med 133:964-968.
31. Sallustio BC, Harkin LA, Mann MC, Krivickas SJ, and Burcham PC (1997) Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycone? Toxicol Appl Pharmacol 147:459-464.
32. Sallustio BC and Holbrook FL (2001) In vivo perturbation of rat hepatocyte canalicular membrane function by diclofenac. Drug Metab Dispos 29:1535-1538.
33. Sausen PJ and Elfarra AA (1991) Reactivity of cysteine S-conjugate sulfoxides: formation of S-[1-chloro-2-(S-glutathionyl)vinyl]-L-cysteine sulfoxide by the reaction of S-(1,2-dichlorovinyl)-L-cysteine sulfoxide with glutathione. Chem Res Toxicol 4:655-660.
34. Seitz S and Boelsterli UA (1998) Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115:1476-1482.
35. Smith GS, Nadig DE, Kokoshka ER, Solomon H, Tiniakos DG, and Miller TA (1998) Role of neutrophils in hepatotoxicity induced by oral acetaminophen administration in rats. J Surg Res 80:252-258.
36. Soars MG, Riley RJ, Findlay KAB, Coffey MJ, and Burchell B (2001) Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 29:121-126.
37. Strom SC, Jirtle RL, Jones RS, Novicki DL, Rosenberg MR, Novotny A, Irons G, McLain JR, and Michalopoulos G (1982) Isolation, culture and transplantation of human hepatocytes. J Natl Cancer Inst 68:771-778.
38. Tettey JN, Skellern GG, Midgley JM, Grant MH, Wilkinson R, and Pitt AR (1999) Intracellular localization and metabolism of the phenanthridinium trypanocide, ethidium bromide, by isolated rat hepatocytes. Xenobiotica 29:349-360.
39. Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, Keenan RM, Ku TW, Lundberg D, Miller WH, et al. (1999) Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist. Drug Metab Dispos 27:1232-1241.
40. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD, Armstrong VW, and Oellerich M (2000) Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects. Clin Biochem 33:107-113.